Financing ·
Anika Therapeutics, Inc. entered into a Fifth Amendment to its existing revolving line of credit agreement with Bank…
ANIKAnika Therapeutics, Inc.
Anika Therapeutics, Inc. entered into a Fifth Amendment to its existing revolving line of credit agreement with Bank of America, N.A. to increase its senior revolving line of credit from $50.0 million to a maximum aggregate commitment of $100.0 million. The facility matures on July 10, 2031, and interest rates are based on the Secured Overnight Financing Rate (SOFR) plus a margin of 0.25% to 1.25% depending on the leverage ratio. Anika Therapeutics, Inc. is a biotechnology company that develops and commercializes medical devices and pharmaceuticals for orthopedic and regenerative medicine.